European PromarkerD patents expanded beyond diabetes

Proteomics International Laboratories Ltd is pleased to announce that its European patent protection for the Company’s PromarkerD predictive test has been expanded to include diagnosing all individuals who are prediabetic and asymptomatic for kidney disease.

The International Diabetes Federation estimates there are currently 537 million adults with diabetes, and an additional 541 million (10.6% of the world’s adult population) with prediabetes. Prediabetes is a term used to describe people with impaired glucose tolerance (IGT) – it indicates a higher risk of developing type 2 diabetes and diabetes-related complications such as kidney disease.

Managing Director Dr Lipscombe said the new patent complemented and extended the Company’s existing broad patent family. “The granting of additional patents like this one further strengthens the Company’s IP position,” he said.

ASX Release